AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

SITE MAP - AUSTRALASIAN MENOPAUSE SOCIETY Early onset of menopause and diabetes may limit life span. Midlife women transitioning to menopause have a higher risk of metabolic syndrome, which predisposes to heart disease and type 2 diabetes. Surgical menopause leads to increased sleep issues. Vaginal BIOIDENTICAL HORMONE THERAPY MAIN POINTS. The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they contain hormones identical to those produced in the human body. VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. OESTROGEN AND COGNITION IN THE PERIMENOPAUSE AND MENOPAUSE Cognitive changes associated with the menopause transition include reduced processing speed and reduced verbal memory. Verbal memory is defined as the ability to encode words and it is influenced by circulating oestradiol. MHT has positive or neutral effects of cognitive function in younger peri- or postmenopausal women. BREAST CANCER AND MENOPAUSE AMS Breast Cancer and Menopause 146.46 KB. Introduction. Menopause/menopausal symptoms in women with breast cancer (BC) have a significant negative impact on quality of life, with both short- and long-term health consequences, and can affect BC treatment adherence. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS/THROMBOEMBOLISM Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected COMBINED MENOPAUSAL HORMONE THERAPY (MHT) Combination packs of either cyclical or continuou www.menopause.org.au Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society ABOUT VAGINAL DRYNESS Data from the Study of Women Across the Nation (SWAN) tracked more than 2,400 women over a 17-year-period showed that, at baseline, 19.4% of women (aged 42-53 y) reported vaginal dryness. By the time the women in the study were aged 57 to 69 years, 34% of them complained of symptoms. More surprising, however, is the fact that more than 50% of AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

SITE MAP - AUSTRALASIAN MENOPAUSE SOCIETY Early onset of menopause and diabetes may limit life span. Midlife women transitioning to menopause have a higher risk of metabolic syndrome, which predisposes to heart disease and type 2 diabetes. Surgical menopause leads to increased sleep issues. Vaginal BIOIDENTICAL HORMONE THERAPY MAIN POINTS. The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they contain hormones identical to those produced in the human body. VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. OESTROGEN AND COGNITION IN THE PERIMENOPAUSE AND MENOPAUSE Cognitive changes associated with the menopause transition include reduced processing speed and reduced verbal memory. Verbal memory is defined as the ability to encode words and it is influenced by circulating oestradiol. MHT has positive or neutral effects of cognitive function in younger peri- or postmenopausal women. BREAST CANCER AND MENOPAUSE AMS Breast Cancer and Menopause 146.46 KB. Introduction. Menopause/menopausal symptoms in women with breast cancer (BC) have a significant negative impact on quality of life, with both short- and long-term health consequences, and can affect BC treatment adherence. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS/THROMBOEMBOLISM Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected COMBINED MENOPAUSAL HORMONE THERAPY (MHT) Combination packs of either cyclical or continuou www.menopause.org.au Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society ABOUT VAGINAL DRYNESS Data from the Study of Women Across the Nation (SWAN) tracked more than 2,400 women over a 17-year-period showed that, at baseline, 19.4% of women (aged 42-53 y) reported vaginal dryness. By the time the women in the study were aged 57 to 69 years, 34% of them complained of symptoms. More surprising, however, is the fact that more than 50% of AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. LIFESTYLE AND BEHAVIOURAL MODIFICATIONS FOR MENOPAUSALSEE MORE ON

MENOPAUSE.ORG.AU

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. VULVOVAGINAL SYMPTOMS AFTER MENOPAUSE The changes, which may cause dryness, irritation, itching and pain with intercourse 1-3 are known as the genito-urinary syndrome of menopause (GSM) and can affect up to 50% of postmenopausal women 4. GSM was previously known as atrophic vaginitis or vulvovaginal atrophy (VVA). Unlike some menopausal symptoms, such as hot flushes, which may VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. LIFESTYLE AND BEHAVIOURAL MODIFICATIONS FOR MENOPAUSALSEE MORE ON

MENOPAUSE.ORG.AU

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. VULVOVAGINAL SYMPTOMS AFTER MENOPAUSE The changes, which may cause dryness, irritation, itching and pain with intercourse 1-3 are known as the genito-urinary syndrome of menopause (GSM) and can affect up to 50% of postmenopausal women 4. GSM was previously known as atrophic vaginitis or vulvovaginal atrophy (VVA). Unlike some menopausal symptoms, such as hot flushes, which may VENOUS THROMBOSIS/THROMBOEMBOLISM RISK AND MENOPAUSAL AMS Venous thrombosis/thromboembolism risk and menopausal treatments 317.5 KB. Menopausal hormone therapy (MHT) containing oestrogens in tablet form increase the risk of deep vein thrombosis (DVT) and pulmonary embolus (PE) (1, 2). The thrombotic effects of MHT containing oral oestrogen are associated with a slightly increased

risk of stroke

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

LIFESTYLE AND BEHAVIOUR CHANGES FOR MENOPAUSAL SYMPTOMS wear clothing made of natural fibres that breathe. avoid jumpers and scarves. using a hand fan or electric fan as required. keeping cooler at night. lower the room temperature. put a cold pack under the pillow. turn the pillow over to the cool side when feeling warm. use dual control electric blankets. LIFESTYLE AND BEHAVIOURAL MODIFICATIONS FOR MENOPAUSAL Key Points: Evidence for the effectiveness of lifestyle and behaviour modifications for menopausal symptoms is mixed, limited or non-existent. Evidence suggests that weight gain increases the severity of vasomotor symptoms so maintaining healthy weight might be

helpful.

DIAGNOSING MENOPAUSE Common q www.menopause.org.au Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person’s circumstances and should always be discussed with that person's own healthcare provider. BIOIDENTICAL HORMONE THERAPY MAIN POINTS. The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they contain hormones identical to those produced in the human body. AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

CONTRACEPTION

Advantages: It is highly effective ( > 99% effective in perfect and typical use) (5) It lasts for five years, but use can be extended to seven years if it is inserted over the age of 45 years. It is cost effective after the initial ‘up front’ insertion cost. It is highly effective at reducing TREATMENTS AND THE RISK OF VENOUS THROMBOSIS Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected TOTAL KNEE REPLACEMENT MAY BE MORE PAINFUL FOR VITAMIN-D Vitamin D is a critical part of a healthy diet. Among other benefits, it has been shown to protect against bone disease and maintain soft

tissue health.

TIBOLONE FOR POST-MENOPAUSAL WOMEN 2. Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, Basevi V, Marata AM, Magrini N, Maestri E. Short and long term effects of tibolone in postmenopausal women.Cochrane Database Syst Rev. 2012

Feb 15;2:CD008536.

AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. FAMILIAL RISK ASSESSMENT FRA-BOC Familial Risk Assessment – Breast and Ovarian Cancer (FRA-BOC) is an on-line tool designed for use by health professionals. FRA-BOC: provides an estimation of the risk of developing breast or ovarian cancer, based on family history, for unaffected women i.e. those who have not had a diagnosis of breast cancer or epithelial ovarian cancer THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. ABOUT VAGINAL DRYNESS Data from the Study of Women Across the Nation (SWAN) tracked more than 2,400 women over a 17-year-period showed that, at baseline, 19.4% of women (aged 42-53 y) reported vaginal dryness. By the time the women in the study were aged 57 to 69 years, 34% of them complained of symptoms. More surprising, however, is the fact that more than 50% of HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. FAMILIAL RISK ASSESSMENT FRA-BOC Familial Risk Assessment – Breast and Ovarian Cancer (FRA-BOC) is an on-line tool designed for use by health professionals. FRA-BOC: provides an estimation of the risk of developing breast or ovarian cancer, based on family history, for unaffected women i.e. those who have not had a diagnosis of breast cancer or epithelial ovarian cancer THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. ABOUT VAGINAL DRYNESS Data from the Study of Women Across the Nation (SWAN) tracked more than 2,400 women over a 17-year-period showed that, at baseline, 19.4% of women (aged 42-53 y) reported vaginal dryness. By the time the women in the study were aged 57 to 69 years, 34% of them complained of symptoms. More surprising, however, is the fact that more than 50% of HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

BIOIDENTICAL HORMONE THERAPY MAIN POINTS. The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they contain hormones identical to those produced in the human body.

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

VAGINAL LASER THERAPY Vaginal laser is a new treatment being offered for some menopausal symptoms. There is insufficient high quality evidence for its safety and benefits. Vaginal oestrogen is safe and effective and can be used by most women. Vaginal laser for menopausal symptoms is not approved by regulatory authorities in Australia and the USA. TREATMENTS AND THE RISK OF VENOUS THROMBOSIS Information Sheet Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected PREVENTION OF FALLS AND FRACTURES AMS Prevention of falls and fractures 156.34 KB. Falls are the main cause of fractures or broken bones at any age. A fall is an event during which a person inadvertently comes to rest on the ground or at other lower level (1).Falls are preventable (2,3).. They result in injuries, loss of confidence and subsequent reduction in activity levels and community participation (4). THE PERIMENOPAUSE OR MENOPAUSAL TRANSITION www.menopause.org Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. COMBINED MENOPAUSAL HORMONE THERAPY (MHT) Combination packs of either cyclical or continuou www.menopause.org.au Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society TOTAL KNEE REPLACEMENT MAY BE MORE PAINFUL FOR VITAMIN-D Vitamin D is a critical part of a healthy diet. Among other benefits, it has been shown to protect against bone disease and maintain soft

tissue health.

AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation.

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

BIOIDENTICAL HORMONE THERAPY The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they

contain

TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. MENOPAUSE BEFORE 40 AND SPONTANEOUS POI Premature ovarian insufficiency (POI) is a loss of function of the ovaries in women who are less than 40 years old. Spontaneous POI affects up to 4% of women less than 40 years and in most cases the cause is not identified. Irregular/no menstrual periods or menopausal symptoms may be the only sign of POI and blood tests are needed for

diagnosis.

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation. AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

BIOIDENTICAL HORMONE THERAPY The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they

contain

MENOPAUSE BEFORE 40 AND SPONTANEOUS POI Premature ovarian insufficiency (POI) is a loss of function of the ovaries in women who are less than 40 years old. Spontaneous POI affects up to 4% of women less than 40 years and in most cases the cause is not identified. Irregular/no menstrual periods or menopausal symptoms may be the only sign of POI and blood tests are needed for

diagnosis.

TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia

TREATMENT OPTIONS

The menopause is the final menstrual period and usually happens between the ages of 45 and 55 years. Around this time, women may experience symptoms such as hot flushes, sweating, vaginal dryness, loss of libido, irritability, sleep disturbance and muscle/joint pains. Oestrogen therapy is the most effective means of treating these

symptoms.

DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation.

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

VULVOVAGINAL SYMPTOMS AFTER MENOPAUSE The changes, which may cause dryness, irritation, itching and pain with intercourse 1-3 are known as the genito-urinary syndrome of menopause (GSM) and can affect up to 50% of postmenopausal women 4. GSM was previously known as atrophic vaginitis or vulvovaginal atrophy (VVA). Unlike some menopausal symptoms, such as hot flushes, which may VAGINAL LASER THERAPY Vaginal laser is a new treatment being offered for some menopausal symptoms. There is insufficient high quality evidence for its safety and benefits. Vaginal oestrogen is safe and effective and can be used by most women. Vaginal laser for menopausal symptoms is not approved by regulatory authorities in Australia and the USA.

BOOK REVIEWS

MD, MBBS, MHPEd., FRANZCOG, FRCOG. This book is a wonderfully concise summary of the available treatments for the management of menopausal symptoms. It also takes a fascinating look at menopause itself, in terms of how our understanding of menopause evolved over time, and how treatments were developed by various cultures for treatment of

URO-GENITAL

The following topics concerning the uro-genital areas may be found in the AMS Information Sheets. Stress and Urge Urinary Incontinence in Women Normal bladder function is represented by: a frequency 4-6 per day (0-1 at night); 1-2 cups of urine (250-500mls) are passed; voiding can be deferred until convenient; urine is passed in a steady continuous stream until bladder is empty no leakage ABOUT VAGINAL DRYNESS Data from the Study of Women Across the Nation (SWAN) tracked more than 2,400 women over a 17-year-period showed that, at baseline, 19.4% of women (aged 42-53 y) reported vaginal dryness. By the time the women in the study were aged 57 to 69 years, 34% of them complained of symptoms. More surprising, however, is the fact that more than 50% of TOTAL KNEE REPLACEMENT MAY BE MORE PAINFUL FOR VITAMIN-D Vitamin D is a critical part of a healthy diet. Among other benefits, it has been shown to protect against bone disease and maintain soft

tissue health.

AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation.

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

BIOIDENTICAL HORMONE THERAPY The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they

contain

TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. MENOPAUSE BEFORE 40 AND SPONTANEOUS POI Premature ovarian insufficiency (POI) is a loss of function of the ovaries in women who are less than 40 years old. Spontaneous POI affects up to 4% of women less than 40 years and in most cases the cause is not identified. Irregular/no menstrual periods or menopausal symptoms may be the only sign of POI and blood tests are needed for

diagnosis.

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia AMS HOME - AUSTRALASIAN MENOPAUSE SOCIETYABOUT AMSMEMBERSHEALTH PROFESSIONALSCONSUMER INFORMATIONCHANGES MAGAZINE About the AMS. Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing. Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to

locate a

MENOPAUSE WHAT ARE THE SYMPTOMS? Most women have symptoms for 5 to 10 years. Menopause occurs when you have not had a menstrual period for 12 months. Menopause is a natural part of life occurring at around age 51 years but can also happen for other reasons including after: surgery to remove ovaries (oophorectomy) and/or your womb/uterus (hysterectomy) radiotherapy to

your pelvis.

AMS DIAGNOSING MENOPAUSE: SYMPTOM SCORE SHEET � Australasian Menopause Society 2015 www.menopause.org.au AMS Diagnosing Menopause: Symptom Score Sheet This valuable diagnostic tool can be completed together with A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation.

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

AMS GUIDE TO EQUIVALENT MHT/HRT DOSES AUSTRALIA ONLY AMS Guide to Equivalent MHT/HRT Doses Australia only. This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in May 2020. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to

help physicians

BIOIDENTICAL HORMONE THERAPY The Australasian Menopause Society does not recommend the use of compounded bioidentical hormone therapy in any form. Many pharmaceutical-grade, approved menopause hormone therapies (MHTs) prescribed by your doctor are ‘body-identical’ – i.e. they

contain

TESTOSTERONE AND WOMEN Testosterone blood levels in men are about 10-20 fold greater than in women and result in the male features we tend to associate with testosterone, such as deeper voice, more body hair, more muscle and so forth. Testosterone blood levels in women tend to peak during their 20s. This is followed by a gradual decline with age. MENOPAUSE BEFORE 40 AND SPONTANEOUS POI Premature ovarian insufficiency (POI) is a loss of function of the ovaries in women who are less than 40 years old. Spontaneous POI affects up to 4% of women less than 40 years and in most cases the cause is not identified. Irregular/no menstrual periods or menopausal symptoms may be the only sign of POI and blood tests are needed for

diagnosis.

HRT FOR MENOPAUSAL SYMPTOMS WITH A PAST HISTORY OR … Summary rates VTE in HRT users • Baseline risk 1-1.6 event per 1000 woman years • Oral estrogen increases risk 2-3x so additional 1.5 events per 1000 woman years • Highest risk in first year (RR 4.0 v 2.1 >1yr), risk abates once ceased • ?higher rate opposed v unopposed E (*2.6 v 2.2) • No difference DVT v PE • Highest in women with PHx VTE or hereditary thrombophilia

TREATMENT OPTIONS

The menopause is the final menstrual period and usually happens between the ages of 45 and 55 years. Around this time, women may experience symptoms such as hot flushes, sweating, vaginal dryness, loss of libido, irritability, sleep disturbance and muscle/joint pains. Oestrogen therapy is the most effective means of treating these

symptoms.

DIAGNOSING MENOPAUSE Peri-menopause refers to the time from the onset of menopausal symptoms (some or all of symptoms such as irregular periods, hot flushes, night sweats or sleep disturbance) to the last menstrual period . This can last on average 4 to 8 years. Menopause is the last menstrual period. One year after the last menstrual period the

woman is

A PRACTITIONER’S TOOLKIT FOR THE MANAGEMENT OF THE MENOPAUSE A Practitioner’s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences womenshealth.med.monash.edu Endorsed by the Australasian Menopause Society, the International Menopause Society and the Jean Hailes Foundation.

FIND AN AMS DOCTOR

Find an AMS doctor. To help you find a doctor who is right for you, the AMS has assembled this search feature of AMS Members who: have a special interest in women's health in midlife and menopause, and the promotion of healthy ageing, and. have requested to be included on the

list.

VULVOVAGINAL SYMPTOMS AFTER MENOPAUSE The changes, which may cause dryness, irritation, itching and pain with intercourse 1-3 are known as the genito-urinary syndrome of menopause (GSM) and can affect up to 50% of postmenopausal women 4. GSM was previously known as atrophic vaginitis or vulvovaginal atrophy (VVA). Unlike some menopausal symptoms, such as hot flushes, which may VAGINAL LASER THERAPY Vaginal laser is a new treatment being offered for some menopausal symptoms. There is insufficient high quality evidence for its safety and benefits. Vaginal oestrogen is safe and effective and can be used by most women. Vaginal laser for menopausal symptoms is not approved by regulatory authorities in Australia and the USA.

BOOK REVIEWS

MD, MBBS, MHPEd., FRANZCOG, FRCOG. This book is a wonderfully concise summary of the available treatments for the management of menopausal symptoms. It also takes a fascinating look at menopause itself, in terms of how our understanding of menopause evolved over time, and how treatments were developed by various cultures for treatment of

URO-GENITAL

The following topics concerning the uro-genital areas may be found in the AMS Information Sheets. Stress and Urge Urinary Incontinence in Women Normal bladder function is represented by: a frequency 4-6 per day (0-1 at night); 1-2 cups of urine (250-500mls) are passed; voiding can be deferred until convenient; urine is passed in a steady continuous stream until bladder is empty no leakage ABOUT VAGINAL DRYNESS Data from the Study of Women Across the Nation (SWAN) tracked more than 2,400 women over a 17-year-period showed that, at baseline, 19.4% of women (aged 42-53 y) reported vaginal dryness. By the time the women in the study were aged 57 to 69 years, 34% of them complained of symptoms. More surprising, however, is the fact that more than 50% of TOTAL KNEE REPLACEMENT MAY BE MORE PAINFUL FOR VITAMIN-D Vitamin D is a critical part of a healthy diet. Among other benefits, it has been shown to protect against bone disease and maintain soft

tissue health.

* Contact us

* Feedback

* Help

* Links

* Media

* Site Map

* Home

* About AMS

* AMS Executive and Board * AMS Board Nominations 2019-21

* AMS Constitution

* AMS Annual Reports * Mission and Vision * Document on Conflict of Interest

* Accreditation

* HON Affiliation

* Code of Ethics

* Contact us

* Feedback

* Media

* AMS in the media

* Media Kit

* Privacy Statement

* Sitemap

* Features

* What's New

* Website Help

* Members

* Members Login

* Members Help

* Membership Application * Membership Renewal

* Changes Magazine

* IMS Menopause Live * Health Professionals * 17th World Congress on the Menopause * 17th World Congress on the Menopause Films

* AMS Congress

* Past Congress Meetings

* Conferences

* HP eNews

* Information Sheets * Information Sheets by Management Area * Menopause Management

* Menopause Basics

* Treatment Options

* Early Menopause

* Risks and Benefits

* Uro-genital

* Bones

* Sex and Psychological * Alternative Therapies

* Contraception

* Menopause - a Primer * Menopause NAMS Videos * NAMS Annual Meeting 2017

* Cochrane Reviews

* Books

* Education

* Menopause Essentials Update

* eDM MEU

* GP & HP Resources

* Links

* Journals

* Medical Databases

* News

* Position Statements

* Studies published

* Consumer Information * Find an AMS doctor

* ACT

* NSW

* NT

* QLD

* SA

* TAS

* VIC

* WA

* New Zealand

* Book Reviews

* Infographics

* Menopause what are the symptoms? * Maintaining your weight and health during and after menopause * What is Menopausal Hormone Therapy (MHT) and is it safe? * Maori: Menopause what are the symptoms? * Maori: What is Menopausal Hormone Therapy (MHT) and is it safe? * Vietnamese: Menopause what are the symptoms? * Vietnamese: What is Menopausal Hormone Therapy (MHT) and is it

safe?

* News

* Resources

* Fact Sheets

* Menopause what are the symptoms? * Non-hormonal treatment options for menopausal symptoms * What is Menopausal Hormone Therapy (MHT) and is it safe? * Complementary medicine options for menopausal symptoms * Will menopause affect my sex life? * Bioidentical Hormone Therapy * 9 myths and misunderstandings about MHT * Lifestyle and behaviour changes for menopausal symptoms * Menopause before 40 and spontaneous POI * Early menopause – chemotherapy and radiation therapy * Maintaining your weight and health during and after menopause * Vaginal health after breast cancer: A guide for patients * Vaginal Laser Therapy * Decreasing the risk of falls and fractures * Urinary Incontinence in Women * Menopause Videos for Women from NAMS * Menopause Videos Cantonese * Menopause Videos Mandarin * Menopause Videos Vietnamese

* Menopause Videos

* Menopause - What are the symptoms * Menopause - How will it affect my health? * What is Menopausal Hormone Therapy (HRT)? * Is Menopausal Hormone Therapy (HRT) safe? * Menopause - Complementary Therapies * Menopause - Non-hormonal Treatment Options * Menopause - Will it affect my sex life? * Self Assessment Tools * Are you at risk of breast cancer? * Are you at risk of cardiovascular disease? * Are you at risk of osteoporotic fracture? * Statin/Aspirin Choice Decision Aid

* Know your bones

* Know your chances

* Risk Checker - 5 minute health questionnaire * Studies Recruiting

*

17TH WORLD CONGRESS ON MENOPAUSE Date moved: now Melbourne

3-7 February 2021

Read more

*

HEALTH INFORMATION

Find an AMS Doctor, news, self-assessment tools and videos

Read more

*

MENOPAUSE MANAGEMENT AMS supporting women through midlife health and the menopause

Read more

*

HEALTH PROFESSIONALS Menopause management resources, news, position statements

Read more

*

MENOPAUSE VIDEOS

Explaining issues women

worry most about

Read more

*

AMS ELEARNING

A benefit for AMS Members webinars, case studies with CPD points

Read more

AMS ELEARNING FOR MEMBERS AMS eLearning is a benefit for AMS members only who will be able to access webinars, case studies, quizzes and other learning that will attract CPD points. Members register here.

CONGRESS NEWS 2020

The 17th World Congress on the Menopause in Melbourne hosted by the IMS with the support of the AMS now moved 4-7 February 2021. Go to 17th World Congress page. WHAT'S NEW | FEATURES View the latest articles available on the AMS website. See What's New

here .

View articles, resources, position statement or events of particular interest. See Features here .

AMS FACT SHEETS

AMS has created a set of fact sheets for patients. These documents are companion sheets to the popular videos , and our other more detailed AMS Information Sheets . The first three sheets

are available.

Learn more here.

MEMBERS

If your work focuses on menopause and issues related to women's midlife health, become a Member of the AMS. Access information and resources which will inspire and guide improvements for your practice. Members only information | Log in . HEALTH PROFESSIONALS Health Professionals includes AMS Congress updates, information sheets, menopause management resources, news, position statements, a selection of studies published, NAMS videos and more... See Health Professionals.

ABOUT THE AMS

Members of the Australasian Menopause Society Limited (AMS) are doctors and other health care professionals who each have a special interest in women's health in midlife and menopause, and the promotion

of healthy ageing.

Whether information is needed about peri-menopause, MHT/HRT and alternatives, osteoporosis or how to locate a doctor interested in women's health, the AMS seeks to bring accurate, evidence-based information to health care workers and the wider community.

Continue Reading

WHAT'S NEW ON AMS

*

NEW INSIGHTS INTO MENOPAUSE AND WEIGHT GAIN Can women in menopause get the benefits of hormone replacement therapy without the risks? A new UCLA study conducted with mice points in that directio... Read more.

*

SOCIOECONOMICS, METABOLIC SYNDROME, AND OSTEOPENIA IN POSTMENOPAUSAL

WOMEN

The increased prevalence of metabolic syndrome and osteoporosis in postmenopausal women has prompted multiple research studies to understand why. A ne... Read more.

*

WHAT IS NEW IN HORMONE THERAPY? JoAnn V. Pinkerton, MD, NCMPNAMS Executive Director Emeritus Professor of Obstetrics and GynecologyDivision Director of Midlife HealthThe University o... Read more.

*

EXECUTIVE FUNCTION IN WOMEN POST-MENOPAUSE Study underscores the importance of considering psychological state during medical procedures. Assessing adverse childhood experiences and current an... Read more.

*

NOT ALL HORMONE THERAPY PROTECTS EQUALLY AGAINST HEART DISEASE IN POSTMENOPAUSAL WOMEN New study based on KEEPS data suggests that oral conjugated equine estrogens slow down adverse effects of heart fat deposition leading to atherosclero... Read more.

AMS FEATURES

*

ENDOMETRIOSIS – MANAGEMENT AFTER MENOPAUSE Key Points Medical management with either the combined oral contraceptive pill or treatments that create a hypo-oestrogenic state are use... Read more..

*

BREAST CANCER AND MENOPAUSE Key Points Menopause/menopausal symptoms in women with breast cancer have a significant negative impact on quality of life, with both

sho... Read more..

*

MIGRAINE HEADACHES, MENOPAUSE AND MHT/HRT KEY POINTS Migraine is not a contraindication to using menopausal hormone therapy Migraine without aura is more sensitive to hormonal

flux... Read more..

*

MAORI: MENOPAUSE WHAT ARE THE SYMPTOMS? Download Infographic: Menopause - What are the symptoms - Maori564.69 KB  If you have any concerns or questions about options to man... Read more..

*

MAORI: WHAT IS MENOPAUSAL HORMONE THERAPY (MHT) AND IS IT SAFE? Download Infographic: What is Menopausal Hormone Therapy (MHT) and is it safe? Maori812.62 KB       If you have any concer... Read

more..

FIND A DOCTOR

Find an AMS doctor

with a specific interest in women's health at midlife and menopause, and the promotion of healthy ageing.

HP ENEWS

This site complies with the HONcode standard for trustworthy health

information:

verify here.

MENOPAUSE MANAGEMENT * Menopause Treatment Options * Menopause Management * Alternative Therapies

* Menopause Basics

* Bones

* Risks and Benefits

* Contraception

* Early Menopause

* Sex and Psychological

* Uro-genital

TOP INFORMATION SHEETS * AMS Guide to Equivalent MHT/HRT Doses Australia only * Oestrogen Only Menopausal Hormone Therapy * Complementary and Herbal Therapies for Hot Flushes | New: January

2018

* What is menopause? * Surgical Menopause * Bioidentical custom compounded hormone therapy * NonHormonal Treatments for Menopausal Symptoms * Vulvovaginal symptoms after menopause * Diagnosing Menopause * Bleeding – perimenopausal, postmenopausal and breakthrough

bleeding on MHT/HRT

POSITION STATEMENTS

* International consensus on testosterone treatment for women * Sexual well-being after menopause: an International Menopause

Society White Paper

* Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy * Heavy Menstrual Bleeding Clinical Care Standard 2017 * NAMS 2017 position statement updates guidelines for hormone

therapy use

* Management of menopausal symptoms in women with a history of

breast cancer

STUDIES PUBLISHED

* New insights into menopause and weight gain * Socioeconomics, metabolic syndrome, and osteopenia in postmenopausal women * Executive function in women post-menopause * Not all hormone therapy protects equally against heart disease in postmenopausal women * Living in greener neighbourhoods may postpone the natural onset of

menopause

* Certain fruits and vegetables may result in fewer menopause

symptom

� Australasian Menopause Society Limited

div > .uk-panel'}">

*

*

INFORMATION

Accreditation

Contact us

Disclaimer

Editorial Policy

Feedback

Media

Privacy Statement

Site Map

*

QUICK LINKS

Apply to be a Member

Conferences

eChanges Magazine

Find an AMS Doctor

IMS Live

Infographics

Information Sheets

Member eNews

Members login

*

AMS: ABN 69 867 357 105 | Website by Impagination

__

SEARCH

* Home

* About AMS

* AMS Executive and Board * AMS Board Nominations 2019-21

* AMS Constitution

* AMS Annual Reports * Mission and Vision * Document on Conflict of Interest

* Accreditation

* HON Affiliation

* Code of Ethics

* Contact us

* Feedback

* Media

* AMS in the media

* Media Kit

* Privacy Statement

* Sitemap

* Features

* What's New

* Website Help

* Members

* Members Login

* Members Help

* Membership Application * Membership Renewal

* Changes Magazine

* IMS Menopause Live * Health Professionals * 17th World Congress on the Menopause * 17th World Congress on the Menopause Films

* AMS Congress

* Past Congress Meetings

* Conferences

* HP eNews

* Information Sheets * Information Sheets by Management Area * Menopause Management

* Menopause Basics

* Treatment Options

* Early Menopause

* Risks and Benefits

* Uro-genital

* Bones

* Sex and Psychological * Alternative Therapies

* Contraception

* Menopause - a Primer * Menopause NAMS Videos * NAMS Annual Meeting 2017

* Cochrane Reviews

* Books

* Education

* Menopause Essentials Update

* eDM MEU

* GP & HP Resources

* Links

* Journals

* Medical Databases

* News

* Position Statements

* Studies published

* Consumer Information * Find an AMS doctor

* ACT

* NSW

* NT

* QLD

* SA

* TAS

* VIC

* WA

* New Zealand

* Book Reviews

* Infographics

* Menopause what are the symptoms? * Maintaining your weight and health during and after menopause * What is Menopausal Hormone Therapy (MHT) and is it safe? * Maori: Menopause what are the symptoms? * Maori: What is Menopausal Hormone Therapy (MHT) and is it safe? * Vietnamese: Menopause what are the symptoms? * Vietnamese: What is Menopausal Hormone Therapy (MHT) and is it

safe?

* News

* Resources

* Fact Sheets

* Menopause what are the symptoms? * Non-hormonal treatment options for menopausal symptoms * What is Menopausal Hormone Therapy (MHT) and is it safe? * Complementary medicine options for menopausal symptoms * Will menopause affect my sex life? * Bioidentical Hormone Therapy * 9 myths and misunderstandings about MHT * Lifestyle and behaviour changes for menopausal symptoms * Menopause before 40 and spontaneous POI * Early menopause – chemotherapy and radiation therapy * Maintaining your weight and health during and after menopause * Vaginal health after breast cancer: A guide for patients * Vaginal Laser Therapy * Decreasing the risk of falls and fractures * Urinary Incontinence in Women * Menopause Videos for Women from NAMS * Menopause Videos Cantonese * Menopause Videos Mandarin * Menopause Videos Vietnamese

* Menopause Videos

* Menopause - What are the symptoms * Menopause - How will it affect my health? * What is Menopausal Hormone Therapy (HRT)? * Is Menopausal Hormone Therapy (HRT) safe? * Menopause - Complementary Therapies * Menopause - Non-hormonal Treatment Options * Menopause - Will it affect my sex life? * Self Assessment Tools * Are you at risk of breast cancer? * Are you at risk of cardiovascular disease? * Are you at risk of osteoporotic fracture? * Statin/Aspirin Choice Decision Aid

* Know your bones

* Know your chances

* Risk Checker - 5 minute health questionnaire * Studies Recruiting